摘要 |
Compounds of formula (I): wherein X is N, CH, CCF<SUB>3</SUB>, or C(C<SUB>1-12 </SUB>aliphatic); R<SUP>4 </SUP>is sulfonic acid, C<SUB>1-12 </SUB>aliphatic-sulfonyl, sulfonyl-C<SUB>1-12 </SUB>aliphatic, C<SUB>1-12 </SUB>aliphatic-sulfonyl-C<SUB>1-6 </SUB>aliphatic, C<SUB>1-6 </SUB>aliphatic-amino, R<SUP>7</SUP>-sulfonyl, R<SUP>7 </SUP>sulfonyl-C<SUB>1-12 </SUB>aliphatic, R<SUP>7</SUP>-aminosulfonyl, R<SUP>7</SUP>-aminosulfonyl-C<SUB>1-12 </SUB>aliphatic, R<SUP>7</SUP>-sulfonylamino, R<SUP>7</SUP>-sulfonylamino-C<SUB>1-12 </SUB>aliphatic, aminosulfonylamino, di-C<SUB>1-12 </SUB>aliphatic amino, di-C<SUB>1-12 </SUB>aliphatic aminocarbonyl, di-C<SUB>1-12 </SUB>aliphatic aminosulfonyl, di-C<SUB>1-12 </SUB>aliphatic amino, di-C<SUB>1-12 </SUB>aliphatic aminocarbonyl, di-C<SUB>1-12 </SUB>aliphatic aminosulfonyl-C<SUB>1-12 </SUB>aliphatic, (R<SUP>8</SUP>)<SUB>1-3</SUB>-Arylamino, (R<SUP>8</SUP>)<SUB>1-3</SUB>-Arylsulfonyl, (R<SUP>8</SUP>)<SUB>1-3</SUB>-Aryl-aminosulfonyl, (R<SUP>8</SUP>)<SUB>1-3</SUB>-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R<SUP>5 </SUP>is hydrogen; and further wherein R<SUP>4 </SUP>and R<SUP>5 </SUP>are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.
|